Symjepi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11141540 ADAMIS PHARMS CORP Syringe devices
Oct, 2036

(13 years from now)

Symjepi is owned by Adamis Pharms Corp.

Symjepi contains Epinephrine.

Symjepi has a total of 1 drug patent out of which 0 drug patents have expired.

Symjepi was authorised for market use on 15 June, 2017.

Symjepi is available in solution;intramuscular, subcutaneous dosage forms.

Symjepi can be used as a method for administering a therapeutic dose of epinephrine.

The generics of Symjepi are possible to be released after 20 October, 2036.

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 15 June, 2017

Treatment: A method for administering a therapeutic dose of epinephrine


More Information on Dosage

SYMJEPI family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic